Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment

Brain, Behavior, and Immunity

Volumn 58, Issue , 2016, Pages 261-271

  Alboni, Silvia ^a   Poggini, Silvia ^b   Garofalo, Stefano ^c   Milior, Giampaolo ^c,d   El Hajj, Hassan ^e   Lecours, Cynthia ^e   Girard, Isabelle ^e   Gagnon, Steven ^e   Boisjoly Villeneuve, Samuel ^e   Brunello, Nicoletta ^a   Wolfer, David P ^f   Limatola, Cristina ^c,g   Tremblay, Marie Ève ^e   Maggi, Laura ^c   Branchi, Igor ^b,f  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SORBONNE UNIVERSITÉ   (France)

^e Université Laval   (Canada)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g IRCCS NEUROMED   (Italy)

Author keywords

Antidepressant; Cytokines; Environment; Inflammation; Major depression; Microglia; Plasticity; Serotonin; SSRI; Undirected susceptibility to change hypothesis

Indexed keywords

CYTOKINE; FLUOXETINE; AUTACOID; SEROTONIN UPTAKE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CELL DENSITY; CELL FUNCTION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENCEPHALITIS; ENVIRONMENT; MENTAL STRESS; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOKINES; DEPRESSION; ENCEPHALITIS; ENVIRONMENT; FLUOXETINE; HIPPOCAMPUS; INFLAMMATION MEDIATORS; MALE; MICE, INBRED C57BL; MICROGLIA; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

EID: 84995471812     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.07.155     Document Type: Article

References (87)

1. Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A.A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., Kamalipour, A., Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 26 (2009), 607–611.
2. Alboni, S., Montanari, C., Benatti, C., Blom, J.M., Simone, M.L., Brunello, N., Caggia, F., Guidotti, G., Marcondes, M.C., Sanchez-Alavez, M., Conti, B., Tascedda, F., Constitutive and LPS-regulated expression of interleukin-18 receptor beta variants in the mouse brain. Brain Behav. Immun. 25 (2011), 483–493.
3. Alboni, S., Benatti, C., Montanari, C., Tascedda, F., Brunello, N., Chronic antidepressant treatments resulted in altered expression of genes involved in inflammation in the rat hypothalamus. Eur. J. Pharmacol. 721 (2013), 158–167.
4. Alboni, S., van Dijk, R., Poggini, S., Milior, G., Perrotta, M., Drenth, T., Brunello, N., Wolfer, D.P., Limatola, C., Amrein, I., Cirulli, F., Maggi, L., Branchi, I., Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol. Psychiatry, 2016 in press.
5. Alcocer-Gomez, E., Cordero, M.D., NLRP3 inflammasome: a new target in major depressive disorder. CNS Neurosci. Ther. 20 (2014), 294–295.
6. Alcocer-Gomez, E., de Miguel, M., Casas-Barquero, N., Nunez-Vasco, J., Sanchez-Alcazar, J.A., Fernandez-Rodriguez, A., Cordero, M.D., NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 36 (2014), 111–117.
7. Alcocer-Gomez, E., Ulecia-Moron, C., Marin-Aguilar, F., Rybkina, T., Casas-Barquero, N., Ruiz-Cabello, J., Ryffel, B., Apetoh, L., Ghiringhelli, F., Bullon, P., Sanchez-Alcazar, J.A., Carrion, A.M., Cordero, M.D., Stress-induced depressive behaviors require a functional NLRP3 inflammasome. Mol. Neurobiol., 2015.
8. Andrade, C., Antidepressant augmentation with anti-inflammatory agents. J. Clin. Psychiatry 75 (2014), 975–977.
9. Arnold, M.C., Papanicolaou, D.A., O'Grady, J.A., Lotsikas, A., Dale, J.K., Straus, S.E., Grafman, J., Using an interleukin-6 challenge to evaluate neuropsychological performance in chronic fatigue syndrome. Psychol. Med. 32 (2002), 1075–1089.
10. Audet, M.C., Mangano, E.N., Anisman, H., Behavior and pro-inflammatory cytokine variations among submissive and dominant mice engaged in aggressive encounters: moderation by corticosterone reactivity. Front. Behav. Neurosci., 4, 2010.
11. Bachstetter, A.D., Morganti, J.M., Jernberg, J., Schlunk, A., Mitchell, S.H., Brewster, K.W., Hudson, C.E., Cole, M.J., Harrison, J.K., Bickford, P.C., Gemma, C., Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol. Aging 32 (2011), 2030–2044.
12. Basterzi, A.D., Aydemir, C., Kisa, C., Aksaray, S., Tuzer, V., Yazici, K., Goka, E., IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20 (2005), 473–476.
13. Bessis, A., Bechade, C., Bernard, D., Roumier, A., Microglial control of neuronal death and synaptic properties. Glia 55 (2007), 233–238.
14. Bielecka, A.M., Paul-Samojedny, M., Obuchowicz, E., Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn-Schmiedeberg's Arch. Pharmacol. 382 (2010), 409–417.
15. Branchi, I., The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology 36 (2011), 339–351.
16. Branchi, I., Alboni, S., Maggi, L., The role of microglia in mediating the effect of the environment in brain plasticity and behavior. Front. Cell. Neurosci., 8, 2014, 390.
17. Branchi, I., Santarelli, S., Capoccia, S., Poggini, S., D'Andrea, I., Cirulli, F., Alleva, E., Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. PLoS One, 8, 2013, e62226.
18. Brunello, N., Alboni, S., Capone, G., Benatti, C., Blom, J.M., Tascedda, F., Kriwin, P., Mendlewicz, J., Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 21 (2006), 219–225.
19. Carvalho, L.A., Torre, J.P., Papadopoulos, A.S., Poon, L., Juruena, M.F., Markopoulou, K., Cleare, A.J., Pariante, C.M., Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disord. 148 (2013), 136–140.
20. Chabry, J., Nicolas, S., Cazareth, J., Murris, E., Guyon, A., Glaichenhaus, N., Heurteaux, C., Petit-Paitel, A., Enriched environment decreases microglia and brain macrophages inflammatory phenotypes through adiponectin-dependent mechanisms: relevance to depressive-like behavior. Brain Behav. Immun. 50 (2015), 275–287.
21. Chen, Y.C., Lin, W.W., Chen, Y.J., Mao, W.C., Hung, Y.J., Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators Inflamm., 2010, 2010, 573594.
22. Cheng, Y., Pardo, M., Armini, R.S., Martinez, A., Mouhsine, H., Zagury, J.F., Jope, R.S., Beurel, E., Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav. Immun., 2016.
23. Cohen, A., Houck, P.R., Szanto, K., Dew, M.A., Gilman, S.E., Reynolds, C.F. 3rd, Social inequalities in response to antidepressant treatment in older adults. Arch. Gen. Psychiatry 63 (2006), 50–56.
24. Diamond, M., Kelly, J.P., Connor, T.J., Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 16 (2006), 481–490.
25. Dulawa, S.C., Holick, K.A., Gundersen, B., Hen, R., Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29 (2004), 1321–1330.
26. Eller, T., Vasar, V., Shlik, J., Maron, E., Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008), 445–450.
27. Franco, R., Fernandez-Suarez, D., Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131 (2015), 65–86.
28. Garofalo, S., D'Alessandro, G., Chece, G., Brau, F., Maggi, L., Rosa, A., Limatola, C., Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice. Nat. Commun., 6, 2015, 6623.
29. Ghosh, M., Xu, Y., Pearse, D.D., Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines. J. Neuroinflamm., 13, 2016, 9.
30. Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., Yirmiya, R., Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 13 (2008), 717–728.
31. Gyoneva, S., Traynelis, S.F., Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J. Biol. Chem. 288 (2013), 15291–15302.
32. Haastrup, E., Knorr, U., Erikstrup, C., Kessing, L.V., Ullum, H., No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. J. Neuroimmunol. 243 (2012), 69–72.
33. Hannestad, J., DellaGioia, N., Bloch, M., The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36 (2011), 2452–2459.
34. Heneka, M.T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jardanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U.K., Kummer, M.P., Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 6058–6063.
35. Hewett, S.J., Jackman, N.A., Claycomb, R.J., Interleukin-1beta in central nervous system injury and repair. Eur. J. Neurodegener. Dis. 1 (2012), 195–211.
36. Horikawa, H., Kato, T.A., Mizoguchi, Y., Monji, A., Seki, Y., Ohkuri, T., Gotoh, L., Yonaha, M., Ueda, T., Hashioka, S., Kanba, S., Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog. Neuropsychopharmacol. Biol. Psychiatry 34 (2010), 1306–1316.
37. Horowitz, M.A., Wertz, J., Zhu, D., Cattaneo, A., Musaelyan, K., Nikkheslat, N., Thuret, S., Pariante, C.M., Zunszain, P.A., Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells. Int. J. Neuropsychopharmacol., 18, 2015.
38. Iniguez, C., Gayoso, M.J., Carreres, J., A versatile and simple method for staining nervous tissue using Giemsa dye. J. Neurosci. Methods 13 (1985), 77–86.
39. Janova, H., Bottcher, C., Holtman, I.R., Regen, T., van Rossum, D., Gotz, A., Ernst, A.S., Fritsche, C., Gertig, U., Saiepour, N., Gronke, K., Wrzos, C., Ribes, S., Rolfes, S., Weinstein, J., Ehrenreich, H., Pukrop, T., Kopatz, J., Stadelmann, C., Salinas-Riester, G., Weber, M.S., Prinz, M., Bruck, W., Eggen, B.J., Boddeke, H.W., Priller, J., Hanisch, U.K., CD14 is a key organizer of microglial responses to CNS infection and injury. Glia, 2015.
40. Jazayeri, S., Keshavarz, S.A., Tehrani-Doost, M., Djalali, M., Hosseini, M., Amini, H., Chamari, M., Djazayery, A., Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 178 (2010), 112–115.
41. Ji, W.W., Li, R.P., Li, M., Wang, S.Y., Zhang, X., Niu, X.X., Li, W., Yan, L., Wang, Y., Fu, Q., Ma, S.P., Antidepressant-like effect of essential oil of Perilla frutescens in a chronic, unpredictable, mild stress-induced depression model mice. Chin. J. Nat. Med. 12 (2014), 753–759.
42. Jiang, H., Wang, Z., Wang, Y., Xie, K., Zhang, Q., Luan, Q., Chen, W., Liu, D., Antidepressant-like effects of curcumin in chronic mild stress of rats: involvement of its anti-inflammatory action. Prog. Neuropsychopharmacol. Biol. Psychiatry 47 (2013), 33–39.
43. Juruena, M.F., Pariante, C.M., Papadopoulos, A.S., Poon, L., Lightman, S., Cleare, A.J., Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br. J. Psychiatry 194 (2009), 342–349.
44. Kagaya, A., Kugaya, A., Takebayashi, M., Fukue-Saeki, M., Saeki, T., Yamawaki, S., Uchitomi, Y., Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 43 (2001), 59–62.
45. Kenis, G., Maes, M., Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5 (2002), 401–412.
46. Kim, J.W., Kim, Y.K., Hwang, J.A., Yoon, H.K., Ko, Y.H., Han, C., Lee, H.J., Ham, B.J., Lee, H.S., Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatry Investig. 10 (2013), 294–299.
47. Kraemer, H.C., Frank, E., Kupfer, D.J., Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 296 (2006), 1286–1289.
48. Kubera, M., Maes, M., Kenis, G., Kim, Y.K., Lason, W., Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 134 (2005), 251–258.
49. Lanquillon, S., Krieg, J.C., Bening-Abu-Shach, U., Vedder, H., Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22 (2000), 370–379.
50. Lehnardt, S., Massillon, L., Follett, P., Jensen, F.E., Ratan, R., Rosenberg, P.A., Volpe, J.J., Vartanian, T., Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 8514–8519.
51. Leo, R., Di Lorenzo, G., Tesauro, M., Razzini, C., Forleo, G.B., Chiricolo, G., Cola, C., Zanasi, M., Troisi, A., Siracusano, A., Lauro, R., Romeo, F., Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J. Clin. Psychiatry 67 (2006), 1760–1766.
52. Liu, J., Buisman-Pijlman, F., Hutchinson, M.R., Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder. Front. Neurosci., 8, 2014, 309.
53. Lu, M., Yang, J.Z., Geng, F., Ding, J.H., Hu, G., Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis. Int. J. Neuropsychopharmacol. 17 (2014), 1501–1510.
54. MacQueen, G., Frodl, T., The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol. Psychiatry 16 (2011), 252–264.
55. Maggi, L., Scianni, M., Branchi, I., D'Andrea, I., Lauro, C., Limatola, C., CX(3)CR1 deficiency alters hippocampal-dependent plasticity phenomena blunting the effects of enriched environment. Front. Cell. Neurosci., 5, 2011, 22.
56. Mastronardi, C., Paz-Filho, G.J., Valdez, E., Maestre-Mesa, J., Licinio, J., Wong, M.L., Long-term body weight outcomes of antidepressant-environment interactions. Mol. Psychiatry 16 (2011), 265–272.
57. Milior, G., Lecours, C., Samson, L., Bisht, K., Poggini, S., Pagani, F., Deflorio, C., Lauro, C., Alboni, S., Limatola, C., Branchi, I., Tremblay, M.E., Maggi, L., Fractalkine receptor deficiency impairs microglial and neuronal responsiveness to chronic stress. Brain Behav. Immun., 2015.
58. Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16 (2015), 22–34.
59. Obuchowicz, E., Kowalski, J., Labuzek, K., Krysiak, R., Pendzich, J., Herman, Z.S., Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int. J. Neuropsychopharmacol. 9 (2006), 27–35.
60. Pan, Y., Chen, X.Y., Zhang, Q.Y., Kong, L.D., Microglial NLRP3 inflammasome activation mediates IL-1beta-related inflammation in prefrontal cortex of depressive rats. Brain Behav. Immun. 41 (2014), 90–100.
61. Paolicelli, R.C., Bisht, K., Tremblay, M.E., Fractalkine regulation of microglial physiology and consequences on the brain and behavior. Front. Cell. Neurosci., 8, 2014, 129.
62. Paxinos, G., Franklin, K.B.J., Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates, fourth ed., 2013, Academic Press Elsevier Ed.
63. Ruiz-Perera, L., Muniz, M., Vierci, G., Bornia, N., Baroncelli, L., Sale, A., Rossi, F.M., Fluoxetine increases plasticity and modulates the proteomic profile in the adult mouse visual cortex. Sci. Rep., 5, 2015, 12517.
64. Santello, M., Volterra, A., TNFalpha in synaptic function: switching gears. Trends Neurosci. 35 (2012), 638–647.
65. Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3 (2008), 1101–1108.
66. Singhal, G., Jaehne, E.J., Corrigan, F., Toben, C., Baune, B.T., Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci., 8, 2014, 315.
67. Skelly, D.T., Hennessy, E., Dansereau, M.A., Cunningham, C., A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1beta, [corrected] TNF-alpha and IL-6 challenges in C57BL/6 mice. PLoS One, 8, 2013, e69123.
68. Smiley, J.F., Bleiwas, C., Embedding matrix for simultaneous processing of multiple histological samples. J. Neurosci. Methods 209 (2012), 195–198.
69. Song, C., Halbreich, U., Han, C., Leonard, B.E., Luo, H., Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42 (2009), 182–188.
70. Tianzhu, Z., Shihai, Y., Juan, D., Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress. Evid. Based Complement. Altern. Med. eCAM, 2014, 2014, 438506.
71. Tremblay, M.E., Zettel, M.L., Ison, J.R., Allen, P.D., Majewska, A.K., Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia 60 (2012), 541–558.
72. ∗D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
73. Trotta, T., Porro, C., Calvello, R., Panaro, M.A., Biological role of Toll-like receptor-4 in the brain. J. Neuroimmunol. 268 (2014), 1–12.
74. Tuglu, C., Kara, S.H., Caliyurt, O., Vardar, E., Abay, E., Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170 (2003), 429–433.
75. Tynan, R.J., Weidenhofer, J., Hinwood, M., Cairns, M.J., Day, T.A., Walker, F.R., A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav. Immun. 26 (2012), 469–479.
76. Walker, F.R., Beynon, S.B., Jones, K.A., Zhao, Z., Kongsui, R., Cairns, M., Nilsson, M., Dynamic structural remodelling of microglia in health and disease: a review of the models, the signals and the mechanisms. Brain Behav. Immun. 37 (2014), 1–14.
77. Wang, J.W., David, D.J., Monckton, J.E., Battaglia, F., Hen, R., Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. 28 (2008), 1374–1384.
78. Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J., Greengard, P., Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 9262–9267.
79. Wilson, C.B., McLaughlin, L.D., Ebenezer, P.J., Nair, A.R., Dange, R., Harre, J.G., Shaak, T.L., Diamond, D.M., Francis, J., Differential effects of sertraline in a predator exposure animal model of post-traumatic stress disorder. Front. Behav. Neurosci., 8, 2014, 256.
80. Wohleb, E.S., Hanke, M.L., Corona, A.W., Powell, N.D., Stiner, L.M., Bailey, M.T., Nelson, R.J., Godbout, J.P., Sheridan, J.F., Beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J. Neurosci. 31 (2011), 6277–6288.
81. Wong, M.L., Licinio, J., Research and treatment approaches to depression. Nat. Rev. Neurosci. 2 (2001), 343–351.
82. Xia, Z., DePierre, J.W., Nassberger, L., Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34 (1996), 27–37.
83. Xie, H., Jin, D., Kang, Y., Shi, X., Liu, H., Shen, H., Chen, J., Yan, M., Liu, J., Pan, S., The effect of Piper laetispicum extract (EAE-P) during chronic unpredictable mild stress based on interrelationship of inflammatory cytokines, apoptosis cytokines and neurotrophin in the hippocampus. BMC Complement. Altern. Med., 15, 2015, 240.
84. Yirmiya, R., Goshen, I., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25 (2011), 181–213.
85. Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Ueda, N., Nakamura, J., Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009), 722–726.
86. Zhang, Y., Liu, L., Liu, Y.Z., Shen, X.L., Wu, T.Y., Zhang, T., Wang, W., Wang, Y.X., Jiang, C.L., NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int. J. Neuropsychopharmacol., 18, 2015.
87. Zhou, M., Wang, C.M., Yang, W.L., Wang, P., Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia. Brain Res. 1506 (2013), 105–114.